Sulabh Pharmaceutical Profile
Key Indicators
- Authorised Capital ₹ 5.00 Cr
- Paid Up Capital ₹ 5.24 M
- Company Age 12 Year, 11 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 12.00 Cr
- Revenue Growth %
- Profit Growth 1.09%
- Ebitda -0.53%
- Net Worth -123.94%
- Total Assets -94.58%
About Sulabh Pharmaceutical
Sulabh Pharmaceutical Private Limited (SPPL) is a Private Limited Indian Non-Government Company incorporated in India on 14 March 2012 and has a history of 12 years and 11 months. Its registered office is in Mumbai, Maharashtra, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 5.00 Cr and a paid-up capital of Rs 5.24 M.
The company currently has active open charges totaling ₹12.00 Cr.
Anita Prajapati and Pravinkumar Prajapati serve as directors at the Company.
Company Details
-
Location
Mumbai, Maharashtra, India
-
Telephone
+91-XXXXXXXXXX
- Email Address
-
Website
-
-
Social Media
-
Corporate Identity Details
-
CIN/LLPIN
U51101MH2012PTC228079
-
Company No.
228079
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
14 Mar 2012
-
Date of AGM
30 Sep 2023
-
Date of Balance Sheet
31 Mar 2023
-
Listing Status
Unlisted
-
ROC Code
Roc Mumbai
Industry
Who are the key members and board of directors at Sulabh Pharmaceutical?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Anita Prajapati
|
Director | 14-Mar-2012 | Current |
|
Pravinkumar Prajapati
|
Director | 14-Mar-2012 | Current |
Financial Performance of Sulabh Pharmaceutical.
Sulabh Pharmaceutical Private Limited, for the financial year ended 2021, experienced no change in revenue, with a 0% increase. The company also saw a slight improvement in profitability, with a 1.09% increase in profit. The company's net worth observed a substantial decline by a decrease of 123.94%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Sulabh Pharmaceutical?
In 2023, Sulabh Pharmaceutical had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Dhruv Wellness LimitedAnita Prajapati and Pravinkumar Prajapati are mutual person
-
Dashanam Wellness Private Limited
Anita Prajapati and Pravinkumar Prajapati are mutual person
Charges (Loans)
₹12.00 Cr
₹0
Charges Breakdown by Lending Institutions
- Others : 12.00 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 07 Oct 2016 | Others | ₹12.00 Cr | Open |
How Many Employees Work at Sulabh Pharmaceutical?
Unlock and access historical data on people associated with Sulabh Pharmaceutical, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Sulabh Pharmaceutical, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Sulabh Pharmaceutical's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
